A Contemporary Cancer Network OncView Program
A panel of experts from the Tisch Cancer Institute at Mount Sinai and the Icahn School of Medicine at Mount Sinai share insights on biomarker testing protocols and best practices, biomarkers found in non-small cell lung cancer, and current and emerging treatments. They also share strategies for managing adverse events and for providing supportive care for patients.
EP. 1: Biomarker Testing Best Practices in NSCLC
Non-small cell lung cancer experts share biomarker testing protocols and best practices for optimal outcomes, with a focus on overcoming challenges and nuances of testing.
EP. 2: Important NSCLC Biomarkers
Fred R. Hirsch, MD, PhD, leads a discussion with his Mount Sinai colleagues about important biomarkers found in non-small cell lung cancer, including those that provide predictive and prognostic information.
EP. 3: Choosing the Optimal NSCLC Treatment
A group of experts discuss the current treatment algorithm for NSCLC, as well as novel approaches under investigation, the impact of molecular biomarkers on their treatment decisions, and the importance of clinical trials.
EP. 4: Providing Supportive Care to Patients with NSCLC
Helping patients manage potential treatment-related adverse events is an essential part of the overall care plan in the treatment of non-small cell lung cancer. Experts provide strategies to address adverse events and best practices for providing the supportive care needed for patients.
